FAQ on Lantern Pharma Inc.’s AI-Powered Platform and Its Impact on Lung Cancer Treatment

What is Lantern Pharma Inc.’s RADR® platform?

RADR® is Lantern Pharma’s proprietary AI platform that guides oncology drug development by enabling rapid drug candidate identification and targeted trial design based on genomic and biomarker data.

What were the results of the Phase 2 HARMONIC(TM) trial?

A patient with advanced non-small cell lung cancer (NSCLC) achieved a complete response in their primary cancer lesions after multiple prior therapies failed, remaining responsive to LP-300 for over two years, indicating durable clinical benefit.

Why is this trial outcome significant?

The outcome is significant because it demonstrates the potential of AI-powered drug development to identify effective treatments for patients who have not responded to previous therapies, including immunotherapy and targeted kinase inhibitors.

Who is the target population for LP-300?

The target population is never-smokers with non-small cell lung cancer, representing a growing global unmet need estimated at over $4 billion annually.

How does Lantern Pharma’s approach compare to traditional drug development?

Lantern Pharma leverages AI and machine learning to accelerate and refine the drug development process, potentially identifying effective treatments more quickly and accurately than traditional methods.

Where can I find more information about Lantern Pharma Inc.?

More information is available in the company’s newsroom at https://ibn.fm/LTRN and on their website.

What is the estimated market need for the target population?

The target population, never-smokers with non-small cell lung cancer, represents a growing global unmet need estimated at over $4 billion annually.

How long has the patient remained responsive to LP-300?

The patient has remained responsive to LP-300 for over two years, signaling durable clinical benefit in this challenging population.